Show simple item record

dc.contributor.authorBresnahan, Rebecca
dc.contributor.authorWilliamson, John
dc.contributor.authorMartin-McGill, Kirsty J.
dc.contributor.authorMichael, Benedict D.
dc.contributor.authorMarson, Anthony G.
dc.date.accessioned2019-10-31T01:53:51Z
dc.date.available2019-10-31T01:53:51Z
dc.date.issued2019-10-22
dc.identifierdoi: 10.1002/14651858.cd004154.pub5
dc.identifier.citationBresnahan, R., Martin‐McGill, K. J., Williamson, J., Michael, B. D., & Marson, A. G. (2019). Clobazam add‐on therapy for drug‐resistant epilepsy. Cochrane Database of Systematic Reviews, (10). https://doi.org/10.1002/14651858.CD004154.pub5
dc.identifier.doi10.1002/14651858.CD004154.pub5
dc.identifier.urihttp://hdl.handle.net/10034/622778
dc.descriptionThis article is not available on ChesterRep
dc.description.abstractEpilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug treatment. Clobazam is a 1,5‐benzodiazepine and is commonly used as an add‐on treatment for drug‐resistant epilepsy. This review is an updated version of the original Cochrane Review, first published in 2008, and examines the most current literature regarding clobazam as an add‐on for drug‐resistant epilepsy.
dc.publisherWiley
dc.relation.urlhttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004154.pub5/full
dc.sourceeissn: 1465-1858
dc.titleClobazam add-on therapy for drug-resistant epilepsy
dc.typeArticle
dc.date.updated2019-10-31T01:53:51Z


This item appears in the following Collection(s)

Show simple item record